Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On
On
Under the NYSE's rules, if the Company determines that, if necessary, it will
cure the stock price deficiency by taking an action that will require
stockholder approval, it must so inform the NYSE in the above referenced
notification and the price condition will be deemed cured if the price promptly
exceeds
The Company's common stock will continue to be listed and trade on the NYSE during this period, subject to the Company's compliance with other NYSE continued listing standards.
Item 7.01. Regulation FD Disclosure.
As required by Section 802.01C of the NYSE Listed Company Manual, the Company
issued a press release on
The information in this Item 7.01, including the information contained in Exhibit 99.1 of this Current Report on Form 8-K, is being furnished herewith and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, regardless of any general incorporation language in such filing.
Forward Looking Statements
This Current Report on Form 8-K includes "forward-looking statements" within the
meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act. These statements express a belief, expectation or intention and are
generally accompanied by words that convey projected future events or outcomes.
For example, statements regarding the Company's intention to consider
alternatives to cure the NYSE continued listing requirement deficiency are
forward-looking statements. We have based these forward-looking statements on
our current expectations and assumptions and analyses made by us in light of our
experience and our perception of historical trends, current conditions and
expected future developments, as well as other factors we believe are
appropriate under the circumstances. However, whether actual results and
developments will conform with our expectations and predictions is subject to a
number of risks and uncertainties, many of which are beyond our control,
including the Company's ability to regain compliance with the continued listing
standards of the NYSE within the applicable cure period, the Company's ability
to continue to comply with applicable listing standards of the NYSE and the
other important factors set forth under the caption "Risk Factors" in the
Company's Registration Statement on Form S-1 filed with the
--------------------------------------------------------------------------------
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits Exhibit Number Description 99.1 Press Release ofD-Wave Quantum Inc. , datedMarch 21, 2023 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source